Are fluoroquinolones linked to an increased risk of aortic or mitral regurgitation? This possible association has been examined in a recently published pharmacoepidemiological study. Data from the FDA adverse reporting system database was used to analysed for a a disproportionality analysis, and a random sample of 9,053,240 patients from the U.S. PharMetrics Plus database (IQVIA) was used for the matched nested case-control study. Current fluoroquinolone exposure was classed as an active prescription at the index date or 30 days prior to the event date, recent exposure was use within days 31 to 60 and “past use” was in the range spanning days 61 to 365 prior to the event date. Rate ratios (RRs) were compared to users of amoxicillin and azithromycin. The adjusted RRs for current users of FQ compared with amoxicillin and azithromycin users were 2.40 (95% CI: 1.82 to 3.16) and 1.75 (95% CI: 1.34 to 2.29), respectively. The adjusted RRs for recent and past FQ users when compared with amoxicillin were 1.47 (95% CI: 1.03 to 2.09) and 1.06 (95% CI: 0.91 to 1.21), respectively. The risk of aortic and mitral regurgitation was found to be highest with current fluoroquinolone use, but no elevated risk was associated with past use of FQs. Read details of the study here.
Recent Posts
Archives
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018